Apr 17, 2019
Stealth BioTherapeutics Releases Promising Results from TAZPOWER Open-Label Extension Study in Barth Syndrome
Apr 16, 2019
Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial
Apr 04, 2019
Stealth BioTherapeutics Reports Fiscal Year 2018 Financial Results and Recent Business Highlights
Apr 02, 2019
Stealth BioTherapeutics to Present at H.C. Wainwright Global Life Sciences Conference
Mar 04, 2019
Stealth BioTherapeutics Announces Partial Exercise and Closing of Over-Allotment Option
Dec 10, 2018
Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy
Jun 18, 2018
Stealth BioTherapeutics Announces $100M Financings to Advance Clinical Development of Elamipretide and Pipeline
Apr 30, 2018
Stealth BioTherapeutics Granted Orphan Drug Designation of Elamipretide for Treatment of Leber's Hereditary Optic Neuropathy
Apr 09, 2018
Stealth BioTherapeutics Granted Orphan Drug Designation for Elamipretide for Treatment of Barth Syndrome
Mar 06, 2018
Stealth BioTherapeutics Completes Enrollment of Study for the Treatment of Barth Syndrome
Nov 27, 2017
Stealth BioTherapeutics Granted Fast Track Designation for the Treatment of Barth Syndrome
Oct 02, 2017
Stealth BioTherapeutics Granted Orphan Drug Designation of Elamipretide for Treatment of Patients with Primary Mitochondrial Myopathy
Aug 07, 2017
Stealth BioTherapeutics Announces New Appointments to its Board of Directors
Jun 15, 2017
Stealth BioTherapeutics to Present Top-Line Data From MMPOWER-2 Phase 2 Continuation Trial at Mitochondrial Medicine Symposium 2017